目的探讨galectin-3在小鼠结肠癌肝转移中的表达及MCP对其抑制的作用。方法75只Balb/c小鼠随机分为阴性对照组,阳性对照组,低浓度MCP组,中浓度MCP组,高浓度MCP组。阳性对照组和各MCP治疗组小鼠经脾脏下极包膜注入CT-26结肠癌细胞建立结肠癌肝转移模型。MCP加入饮用水中,各处理组的浓度分别为0mg/mL,0.01mg/mL,0.025mg/mL和0.05mg/mL。3周后观察各组小鼠肝转移情况。采用酶联免疫吸附实验(ELISA)方法检测小鼠血清galectin-3浓度;制作肝转移瘤组织芯片、用免疫组化方法检测肝转移瘤组织中galectin-3的表达。结果(1)除阴性对照组外各组脾脏原发瘤体积中位数分别为1.51cm3,0.93cm3,0.77cm3和0.70cm3。高浓度MCP组肿瘤体积较对照组明显降低(P<0.05)。(2)除阴性对照组外,各组肝转移率依次为100%,80%,73.3%和60%。高浓度MCP组肝转移灶数目明显低于阳性对照组(P<0.05)。(3)阳性对照组和各治疗组血清galectin-3浓度均明显高于阴性对照组(均为P<0.01);阳性对照组与各治疗组间差异无显著性(P>0.05)。(4)除阴性对照组外,各组肝转移瘤组织中galectin-3表达相互间差异无显著性(P>0.05)。结论galectin-3在结肠癌肝转移中呈高水平表达;MCP能明显抑制结肠癌的肝转移。 Objective To investigate the expression of galectin-3 in liver metastasis of mouse colon cancer and the effect of MCP on it. Methods Seventy Balb / c mice were randomly divided into a negative control group, a positive control group, a low concentration MCP group, a middle concentration MCP group and a high concentration MCP group. The positive control group and each MCP treatment group were injected with CT-26 colon cancer cells through the lower pole of the spleen into a model of hepatic metastasis of colon cancer. MCP was added to drinking water at concentrations of 0 mg / mL, 0.01 mg / mL, 0.025 mg / mL and 0.05 mg / mL for each treatment group. Three weeks later, the liver metastasis in each group was observed. The concentration of galectin-3 in serum was detected by enzyme-linked immunosorbent assay (ELISA). The liver metastasis tissue microarray was prepared and the expression of galectin-3 was detected by immunohistochemistry. Results (1) In addition to negative control group, the median volume of spleen primary tumor in each group were 1.51cm3, 0.93cm3, 0.77cm3 and 0.70cm3, respectively. The tumor volume of high concentration MCP group was significantly lower than that of the control group (P <0.05). (2) In addition to the negative control group, the rates of liver metastases in each group were 100%, 80%, 73.3% and 60%, respectively. The number of liver metastases in high-concentration MCP group was significantly lower than that in positive control group (P <0.05). (3) Serum concentrations of galectin-3 in the positive control group and each treatment group were significantly higher than those in the negative control group (all P <0.01). There was no significant difference between the positive control group and each treatment group (P> 0.05). (4) In addition to the negative control group, there was no significant difference in the expression of galectin-3 among the groups of liver metastases (P> 0.05). Conclusions galectin-3 is highly expressed in liver metastases of colon cancer. MCP can significantly inhibit liver metastasis of colon cancer.